LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Protected Telomeres Keep Precancerous Cells from Entering the Apoptotic Pathway

By LabMedica International staff writers
Posted on 08 Jul 2015
Image: During mitosis, a cell\'s chromosomes (blue) rapidly divide. When the ends of chromosomes called telomeres (green) are no longer protected by the protein TERF2, the cell receives a signal (red) to undergo cell death (Photo courtesy of the Salk Institute).
Image: During mitosis, a cell\'s chromosomes (blue) rapidly divide. When the ends of chromosomes called telomeres (green) are no longer protected by the protein TERF2, the cell receives a signal (red) to undergo cell death (Photo courtesy of the Salk Institute).
A team of molecular and cell biologists has shown that potentially cancerous cells could be eliminated from the body by rendering their telomeres more susceptible to the actions of drugs that block mitosis and direct the cells onto the apoptotic pathway.

A telomere is a region of repetitive nucleotide sequences at each end of a chromosome, which protects the end of the chromosome from deterioration or from fusion with neighboring chromosomes. Telomere regions deter the degradation of genes near the ends of chromosomes by allowing chromosome ends to shorten, which necessarily occurs during chromosome replication. Human telomeres possess a single-stranded DNA (ssDNA) overhang of TTAGGG repeats, which can self-fold into a G-quadruplex structure. Overexpression in cancer cells of the enzyme telomerase, which adds length to telomeres, allows them to divide in perpetuity. Telomerase is activated in most human cancers and is critical for cancer cell growth.

Regular cell mitosis typically takes about 30–45 minutes, while cells about to go into mitotic crisis undergo a mitosis process that lasts 2 to 20 hours or more.

Investigators at the Salk Institute (La Jolla, CA, USA) reported in the June 24, 2015, online edition of the journal Nature that human cells in crisis underwent spontaneous mitotic arrest, resulting in death during mitosis or in the following cell cycle. This process was induced by loss of p53 function and was suppressed by telomerase overexpression.

Increasing mitotic telomere vulnerability by partial TERF2 (Telomeric repeat-binding factor 2) knockdown increased the ratio of cells that died during mitotic arrest and sensitized cancer cells to anti-mitotic drugs. TERF2, which is present at telomeres in metaphase of the cell cycle, is a second negative regulator of telomere length and plays a key role in the protective activity of telomeres.

"We set out to understand the mechanism of cell death in crisis and found a much more active role of telomeres as barriers to tumor development than previously thought," said senior author Dr. Jan Karlseder, professor of molecular and cell biology at the Salk Institute. "It started when we saw that mitosis is longer in cells approaching crisis."

"There was a long-standing hypothesis that turned out to be incorrect: that cells simply start to fuse chromosomes and break apart, generating instability and cell death," said Dr. Karlseder. "What we show instead is it a much more targeted pathway that really only takes one cell cycle to cause crisis—it has nothing to do with the slow and steady accumulation of genomic instability."

Related Links:

Salk Institute


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more